Liu Hao-Yun, Hsiao Chih-Yang, Hu Rey-Heng, Liang Po-Chin, Wu Chih-Horng
Department of Medical Imaging, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
Department of Traumatology, National Taiwan University Hospital, Taipei, Taiwan.
J Hepatocell Carcinoma. 2025 Jun 27;12:1231-1240. doi: 10.2147/JHC.S524399. eCollection 2025.
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide. Although surgical resection and liver transplantation are considered curative, recurrence is common, especially after hepatectomy. Radiofrequency ablation (RFA) offers a minimally invasive alternative for treating recurrent HCC. However, its efficacy is influenced by tumor location and imaging guidance. This study aims to compare the outcomes of CT-guided and US-guided RFA in patients with single small recurrent HCCs located in the subdiaphragmatic region after hepatectomy.
In this retrospective single-center study, we included patients who received RFA for recurrent HCC following curative hepatectomy between 2008 and 2020. Patients were categorized into CT-guided or US-guided RFA groups. RFA was performed by experienced interventional radiologists, and follow-up imaging was conducted every 3-6 months to assess recurrence. The primary outcome was recurrence-free survival (RFS), and the secondary outcome was overall survival (OS).
In this study, 59 and 32 patients with subdiaphragmatic lesions underwent CT-guided- and US-guided RFA, respectively, for single recurrent HCC. The CT-guided group showed larger tumor size, lower recurrence rates, and significantly better RFS in Kaplan-Meier analysis compared to the US-guided group (49.5 months vs 35.7 months, p value= 0.042). Multivariate analysis confirmed a superior RFS hazard ratio (HR=0.551) for CT-guided RFA, although the overall survival showed no significant difference. Major complications were absent in both groups.
CT-guided RFA provides improved RFS for subdiaphragmatic recurrent HCC, highlighting its potential as a preferred technique for challenging anatomical locations. Further multicenter prospective studies are necessary to validate these findings and assess the long-term survival outcomes.
肝细胞癌(HCC)仍是全球癌症相关死亡的主要原因之一。尽管手术切除和肝移植被认为是治愈性的,但复发很常见,尤其是在肝切除术后。射频消融(RFA)为治疗复发性HCC提供了一种微创替代方法。然而,其疗效受肿瘤位置和成像引导的影响。本研究旨在比较CT引导和超声引导下RFA治疗肝切除术后位于膈下区域的单个小复发性HCC患者的疗效。
在这项回顾性单中心研究中,我们纳入了2008年至2020年间因复发性HCC接受RFA治疗的患者,这些患者在根治性肝切除术后接受了RFA治疗。患者被分为CT引导或超声引导RFA组。RFA由经验丰富的介入放射科医生进行,每3 - 6个月进行一次随访成像以评估复发情况。主要结局是无复发生存期(RFS),次要结局是总生存期(OS)。
在本研究中,分别有59例和32例膈下病变患者因单个复发性HCC接受了CT引导和超声引导下的RFA治疗。在Kaplan - Meier分析中,CT引导组显示肿瘤尺寸更大,复发率更低,RFS显著优于超声引导组(49.5个月对35.7个月,P值 = 0.042)。多变量分析证实CT引导下RFA的RFS风险比更高(HR = 0.551),尽管总生存期无显著差异。两组均未出现主要并发症。
CT引导下的RFA为膈下复发性HCC提供了更好的RFS,突出了其作为具有挑战性解剖位置首选技术的潜力,但需要进一步的多中心前瞻性研究来验证这些结果并评估长期生存结局。